Editorials

Preventing Deaths from Methotrexate Overdose
E. Etchells ........................................ 1853

Use of Low-Dose Glucocorticoids and the Risk of Cardiovascular Morbidity and Mortality in Rheumatoid Arthritis: What Is the True Direction of Effect?
J.M. Davis III, H. Maradit-Kremers, S.E. Gabriel ... 1856

Steroids for Rheumatoid Arthritis: The Honeymoon Revisited (Once Again)
L. Caplan, A.S. Russell, F. Wolfe .................... 1863

Malignancy and Rheumatic Disease — A Real Association?
S. Chambers, D. Isenberg ......................... 1866

Bone Mineral Content versus Bone Density in a Population with Osteoarthritis: A New Twist to the Controversy?
H. McDonald-Blumer ............................. 1868

ADAM Proteins as Therapeutic Targets in Loosening of Total Hip Replacement Implants?
S. Naus, J.W. Bartsch ............................... 1870

Race, Scleroderma, and Survival: Why Is There a Difference? M.D. Mayes ......................... 1873

Articles

Household Income and Earnings Losses Among 6,396 Persons with RA
F. Wolfe, K. Michaud, H.K. Choi, R. Williams ........ 1875

Autoimmune Disease Is a Risk Factor for the Development of Non-Hodgkin’s Lymphoma
J. Cuttner, H. Spiera, K. Troy, S. Wallenstein ........ 1884

Demographic and Clinical Factors Associated with In-Hospital Death Among Patients with SSc

Distinct Expression of Adhesion Molecules on Skin Fibroblasts from Patients with Diffuse and Limited SSc. A Pilot Study
F. Iannone, M. Matucci-Cerinic, P.C.F. Falappone, S. Guiducci, M. Cinelli, O. Distler, G. Lapadula .... 1893

The Cochrane Review of Physiotherapy Interventions for AS H. Dagfinrud, T.K. Kvien, K.B. Hagen ........ 1899

IL-1 and NF-κB Polymorphisms in AS in Canada and Korea T-H. Kim, M.A. Stone, P. Rahman, et al .... 1907


Prevalence, Disease Manifestations, and Treatment of PsA in Western Norway T.M. Madland, E.M. Apaiset, A.E. Johannessen, B. Rossebö, J.G. Brun .......... 1918

Factors Associated with Musculoskeletal Disability and Chronic Renal Failure in Clinically Diagnosed Primary Gout J. Alvarez-Nemegyei, J.C. Cen-Pisté, M. Medina-Escobedo, S. Villanueva-Jorge .... 1923

Clinical Effects of Intraarticular Injection of High Molecular Weight Hylanuronal (Orthovisc) in OA of the Knee: A Randomized, Controlled, Multicenter Trial D. Neustadt, J. Caldwell, M. Bell, J. Wade, J. Gimbel .... 1928

The Genetic Contribution and Relevance of Knee Cartilage Defects: Case-Control and Sib-Pair Studies C. Ding, F. Cicuttini, F. Scott, J. Stankovich, H. Cooley, G. Jones ............... 1937

Increased Expression and Processing of ADAM 12 (Meltrin-α) in Osteolysis Associated with Aseptic Loosening of Total Hip Replacement Implants G. Ma, M. Ainola, M. Liljestöm, et al ........ 1943

Increased Bone Mineral Content But Not BMD in the Hip in Surgically Treated Knee and Hip OA L. Sandini, J.P.A. Arkoiği, J.S. Jurvelin, H. Kröger .... 1951


Pediatric Rheumatology


Longitudinal Analysis of a Pediatric Rheumatology Clinic Population A.M. Rosenberg .............. 1992
# Case Reports

**Poststreptococcal Reactive Arthritis with Thoracic Spine Involvement in an Adult**


**Synovial Sarcoma of the Foot Mimicking Acute Gouty Arthritis**

Y. Du, S. Pullman-Mooar, H.R. Schumacher. 2006

**Deaths Following MTX Overdoses by Medical Staff**

I. Sinicina, B. Mayr, G. Mall, W. Keil. 2009

---

# OMERACT 7

**International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, Asilomar, California, USA, May 8-12, 2004**

**Introduction**


**Minimal Disease Activity for RA: A Preliminary Definition**


**Minimal Clinically Important Difference, Low Disease Activity State, and Patient Acceptable Symptom State: Methodological Issues**

F. Tubach, G.A. Wells, P. Ravaud, M. Dougados. 2025

**Challenges and Progress in Adverse Event Ascertainment and Reporting in Clinical Trials**

M.N.D. Lassere, K.R. Johnson, for the OMERACT Drug Safety Working Group. 2030

**Generic Patient Self-Report and Investigator Report Instruments of Therapeutic Safety and Tolerability**

M.N.D. Lassere, K.R. Johnson, S. Van Santen, et al. 2033

**Standardized Assessment of Adverse Events in Rheumatology Clinical Trials: Summary of the OMERACT 7 Drug Safety Module Update**

M.N.D. Lassere, K.R. Johnson, M. Boers, et al. 2037

---

**Application of the OMERACT Filter to Scoring Methods for MRI of the Sacroiliac Joints and the Spine. Recommendations for a Research Agenda at OMERACT 7**


**Selection of a Method for Scoring Radiographs for AS Clinical Trials, by the Assessment in AS Working Group and OMERACT**

D.M.F.M. van der Heijde, R.B.M. Landewé, and the ASAS Working Group. 2048

**MRI of Inflammatory Lesions in the Spine in AC Clinical Trials: Is Paramagnetic Contrast Medium Necessary?**


---

# Correspondence

**Treating Leukocytoclastic Vasculitis Associated with Etanercept Therapy. Is It Necessary to Stop Etanercept?**

A. Juan, B. Ribas, C. Nadal, I. Ros. 2061

**Reply**

N. Mohan. 2061

---

**CTLA-4 –1661A/G and –1772T/C Dimorphisms in Japanese Patients with SLE**

F. Takeuchi, S. Kuwata, M. Mori. 2062

---

**Fibromyalgia Syndrome: Review of Clinical Presentation, Pathogenesis, Outcome Measures, and Treatment**

P. Mease. 2063

---

**Meetings in Rheumatology**